300 likes | 691 Views
Clinical relevance and public health significance of hepatitis B virus genomic variations. 曹广文 主任、教授 第二军医大学流行病学教研室. Geographic distribution of HBV genotypes A-J. J. H,I. Entry of hepatitis B virus. slow replication. strong replication. immune defence. Delayed, vigorous immune response.
E N D
Clinical relevance and public health significance of hepatitis B virus genomic variations 曹广文 主任、教授 第二军医大学流行病学教研室
Entry of hepatitis B virus slow replication strong replication immune defence Delayed, vigorous immune response immunotolerance, inapparent, chronic inapparent transient infection acute incomplete response efficient inefficient fulminant HBsAg carrier chronic hepatitis immunity recovery cirrhosis carcinoma
donor, immuno-selection aa-sequence of S-loop
Model of the HBsAg loop (99-161) : escape mutations in an anti-HBs negative, infectious blood donor I a-determinant C121-C148 L L E G145K T
350 Chang 300 250 200 Colonies 150 100 50 0 pcDNA3.1 HBx HBx∆8 HBx∆11 HBx∆14 HBx∆16 HBx∆18 Transformation 60 x REF 50 40 Foci 30 20 10 x∆8 x∆11 x∆14 0 pcDNA3.1 HBx HBx∆8 HBx∆11 HBx∆14 HBx∆16 HBx∆18 pcDNA3.1 x∆16 x∆18 截短型与野生型HBx在细胞水平的不同功能 Cell Growth Transactivation 80000 a-ML 70000 60000 Luciferase activities 50000 40000 30000 20000 10000 0 pcDNA3.1 HBx HBx∆8 HBx∆11 HBx∆14 HBx∆16 HBx∆18
Transcription factors binding to HBV Enhancer II/Core-promoter
Vaccination and prevalence Vaccination rate (%) HBsAg prevalence (%) Age (years old)
第二军医大学流行病学专业在HBV方面工作 Journal of Clinical Virolology 2007; 38:238-243(通讯作者:曹广文).
Cancer Epidemiology, Biomarkers & Prevention 2010;19(3):777-86 (通讯作者:曹广文)
Carcinogenesis 2008;29(9):1685-91 (通讯作者:曹广文)
Journal of National Cancer Institute2009;101(15):1066-82 (通讯作者:曹广文)
American Journal of Gastroenterology2010 in press (通讯作者:曹广文)
Journal of Gastroenterology 2010 in press(通讯作者:曹广文)
Journal of Medical Viology 2010 in press(通讯作者:曹广文)
Carcinogenesis 2009;30(11):1916-1922 (通讯作者:曹广文)
The important thing is not to stop questioning Albert Einstein 1. How to predict HCC? 2. What kinds of clinical protocol feasible for stopping the progression into HCC? 3. How long does HBV accompany with human evolution? 4. Is there any genetic predisposition for HBV?